The lancet oncology
-
The lancet oncology · Dec 2018
Multicenter StudyLorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy. We aimed to analyse the overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer. ⋯ Pfizer.